Bayer and Soufflé Therapeutics have announced a strategic collaboration and global licensing agreement to advance a cell-specific, heart-targeted small interfering RNA (siRNA) therapy. The partnership focuses on developing a potential treatment for a form of dilated cardiomyopathy, addressing a rare subset of heart disease.
The collaboration will leverage Soufflé’s proprietary technologies to engineer siRNA therapies that are selectively delivered to cardiomyocytes, aiming to improve safety, efficacy, and durability. By combining methods for identifying cell-specific receptors, optimizing ligands, and designing potent siRNA molecules, the approach seeks to overcome traditional challenges in gene therapy delivery, including off-target effects and frequent dosing requirements.
Soufflé Therapeutics focuses on designing potent, precise, and safe medicines for a range of diseases, including skeletal muscle disorders, heart failure, and metabolic conditions.
Bayer continues to advance its cardiovascular and kidney disease pipeline, emphasizing precision cardiology and addressing high unmet medical needs through innovative treatments.
The collaboration aligns with Bayer’s commitment to expanding its portfolio with advanced therapeutic modalities and fostering global health innovation.
The partnership allows Bayer to strengthen its cardiovascular portfolio and enter the emerging field of siRNA-based therapeutics. Soufflé’s integrated platform enables precise delivery of genetic medicines directly to heart muscle cells, with the goal of transforming care for patients with rare heart conditions. Financial terms of the collaboration have not been disclosed.
Also Read